ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy

Autores
Elizalde, Patricia Virginia; Cordo Russo, Rosalia Ines; Chervo, María Florencia; Schillaci, Roxana
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly improved overall survival and cure rates, resistance to available drugs is still a major clinical issue. In its classical mechanism, MErbB-2 activates downstream signaling cascades, which transduce its effects in BC. The fact that ErbB-2 is also present in the nucleus of BC cells was discovered over twenty years ago. Also, compelling evidence revealed a non-canonical function of nuclear ErbB-2 as a transcriptional regulator. As a deeper understanding of nuclear ErbB-2 actions would be crucial to the disclosure of its role as a biomarker and a target of therapy in BC, we will here review its function in BC, in particular, its role in growth, metastatic spreading and response to currently available MErbB-2-positive BC therapies.
Fil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Chervo, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
BREAST CANCER GROWTH
ERBB-2 TRANSCRIPTIONAL ACTIVITY
METASTASIS
NUCLEAR ERBB-2
RESPONSE TO ANTI-ERBB-2 THERAPIES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/110260
Acceder
id CONICETDig_bf107c7a7d1eed878f9df76fed4105af
oai_identifier_str oai:ri.conicet.gov.ar:11336/110260
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapyElizalde, Patricia VirginiaCordo Russo, Rosalia InesChervo, María FlorenciaSchillaci, RoxanaBREAST CANCER GROWTHERBB-2 TRANSCRIPTIONAL ACTIVITYMETASTASISNUCLEAR ERBB-2RESPONSE TO ANTI-ERBB-2 THERAPIEShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly improved overall survival and cure rates, resistance to available drugs is still a major clinical issue. In its classical mechanism, MErbB-2 activates downstream signaling cascades, which transduce its effects in BC. The fact that ErbB-2 is also present in the nucleus of BC cells was discovered over twenty years ago. Also, compelling evidence revealed a non-canonical function of nuclear ErbB-2 as a transcriptional regulator. As a deeper understanding of nuclear ErbB-2 actions would be crucial to the disclosure of its role as a biomarker and a target of therapy in BC, we will here review its function in BC, in particular, its role in growth, metastatic spreading and response to currently available MErbB-2-positive BC therapies.Fil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Chervo, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBioScientifica2016-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/110260Elizalde, Patricia Virginia; Cordo Russo, Rosalia Ines; Chervo, María Florencia; Schillaci, Roxana; ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy; BioScientifica; Endocrine - Related Cancer; 23; 12; 10-2016; 243-2571351-0088CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-16-0360info:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/23/12/T243.xmlinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:00:37Zoai:ri.conicet.gov.ar:11336/110260instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:00:38.022CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
title ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
spellingShingle ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
Elizalde, Patricia Virginia
BREAST CANCER GROWTH
ERBB-2 TRANSCRIPTIONAL ACTIVITY
METASTASIS
NUCLEAR ERBB-2
RESPONSE TO ANTI-ERBB-2 THERAPIES
title_short ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
title_full ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
title_fullStr ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
title_full_unstemmed ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
title_sort ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
dc.creator.none.fl_str_mv Elizalde, Patricia Virginia
Cordo Russo, Rosalia Ines
Chervo, María Florencia
Schillaci, Roxana
author Elizalde, Patricia Virginia
author_facet Elizalde, Patricia Virginia
Cordo Russo, Rosalia Ines
Chervo, María Florencia
Schillaci, Roxana
author_role author
author2 Cordo Russo, Rosalia Ines
Chervo, María Florencia
Schillaci, Roxana
author2_role author
author
author
dc.subject.none.fl_str_mv BREAST CANCER GROWTH
ERBB-2 TRANSCRIPTIONAL ACTIVITY
METASTASIS
NUCLEAR ERBB-2
RESPONSE TO ANTI-ERBB-2 THERAPIES
topic BREAST CANCER GROWTH
ERBB-2 TRANSCRIPTIONAL ACTIVITY
METASTASIS
NUCLEAR ERBB-2
RESPONSE TO ANTI-ERBB-2 THERAPIES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly improved overall survival and cure rates, resistance to available drugs is still a major clinical issue. In its classical mechanism, MErbB-2 activates downstream signaling cascades, which transduce its effects in BC. The fact that ErbB-2 is also present in the nucleus of BC cells was discovered over twenty years ago. Also, compelling evidence revealed a non-canonical function of nuclear ErbB-2 as a transcriptional regulator. As a deeper understanding of nuclear ErbB-2 actions would be crucial to the disclosure of its role as a biomarker and a target of therapy in BC, we will here review its function in BC, in particular, its role in growth, metastatic spreading and response to currently available MErbB-2-positive BC therapies.
Fil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Cordo Russo, Rosalia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Chervo, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description Approximately 15-20% of breast cancers (BC) show either membrane overexpression of ErbB-2 (MErbB-2), a member of the ErbBs family of receptor tyrosine kinases, or ERBB2 gene amplification. Until the development of MErbB-2-targeted therapies, this BC subtype, called ErbB-2-positive, was associated with increased metastatic potential and poor prognosis. Although these therapies have significantly improved overall survival and cure rates, resistance to available drugs is still a major clinical issue. In its classical mechanism, MErbB-2 activates downstream signaling cascades, which transduce its effects in BC. The fact that ErbB-2 is also present in the nucleus of BC cells was discovered over twenty years ago. Also, compelling evidence revealed a non-canonical function of nuclear ErbB-2 as a transcriptional regulator. As a deeper understanding of nuclear ErbB-2 actions would be crucial to the disclosure of its role as a biomarker and a target of therapy in BC, we will here review its function in BC, in particular, its role in growth, metastatic spreading and response to currently available MErbB-2-positive BC therapies.
publishDate 2016
dc.date.none.fl_str_mv 2016-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/110260
Elizalde, Patricia Virginia; Cordo Russo, Rosalia Ines; Chervo, María Florencia; Schillaci, Roxana; ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy; BioScientifica; Endocrine - Related Cancer; 23; 12; 10-2016; 243-257
1351-0088
CONICET Digital
CONICET
url http://hdl.handle.net/11336/110260
identifier_str_mv Elizalde, Patricia Virginia; Cordo Russo, Rosalia Ines; Chervo, María Florencia; Schillaci, Roxana; ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy; BioScientifica; Endocrine - Related Cancer; 23; 12; 10-2016; 243-257
1351-0088
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1530/ERC-16-0360
info:eu-repo/semantics/altIdentifier/url/https://erc.bioscientifica.com/view/journals/erc/23/12/T243.xml
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioScientifica
publisher.none.fl_str_mv BioScientifica
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842979893896282112
score 12.993085

Publicaciones similares